Reel­ing from PD-1 slap­down, In­cyte stirs con­cerns with side ef­fects of oral PD-L1 — al­though drug is al­so 'clear­ly ac­tive'

The re­jec­tion of its PD-1 in­hibitor, reti­fan­limab, was nev­er go­ing to be the end of In­cyte’s check­point sto­ry. Not on­ly was the biotech hold­ing out hope of chang­ing the FDA’s mind and test­ing the can­cer drug in mul­ti­ple com­bi­na­tions, it al­so lined up a trio of oral PD-L1 can­di­dates as next-gen con­tenders for the megablock­buster mar­ket.

But a sur­prise side ef­fect that cropped up in a Phase I tri­al could cast a cloud on the lead oral PD-L1 block­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER